CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer Nov 26, 2018 6:00am EST
CytoDyn Completes Acquisition of ProstaGene and Names Dr. Richard G. Pestell to Board of Directors Nov 19, 2018 6:00am EST
Data from PRO 140 (leronlimab) HIV Monotherapy Trial Selected for Presentation at CROI 2019 Nov 16, 2018 6:00am EST
CytoDyn’s PRO 140 (leronlimab) HIV Monotherapy Trial Results Show 92% Responder’s Rate at 700 mg Dose Nov 13, 2018 6:00am EST
CytoDyn Files IND and Protocol for Phase 1b/2 Clinical Trial in Metastatic Triple-Negative Breast Cancer with PRO 140 (Leronlimab) Nov 05, 2018 6:00am EST
CytoDyn Interim Chief Medical Officer Dr. Richard Pestell to Keynote 11th Annual Conference on Stem Cell and Regenerative Medicine Oct 11, 2018 6:00am EDT
CytoDyn Announces Strategy to Complete Development of Novel ProstaGene Gene-based Prostate Cancer Prognostic Test Oct 09, 2018 6:00am EDT
